Google Newsreel

Loading...

Wednesday, May 22, 2013

Higher Risk of Melanoma in IBD Patients

Gee great!! I'm just gonna die.. my God.  Melanoma was the cancer that killed my mother, making the % higher for me.  I didn't even read the article.  The title says enough.  Maybe one day i'll decide to scan my eyes over the words, but for now I don't feel like going there.  Click the link to go to the original article if you'd like to read it. 




'via Blog this'

Sunday, May 19, 2013

Researchers in #Edinburgh Seek to Identify #Biomarkers in #IBD Patients Using Advanced Techniques

I had no idea the rates of IBD in Scotland were that high.  It seems like researchers and scientists everywhere are looking for the cause and a cure for this horrible chronic illness, but no one has found either.  There are many suggested theories as to the cause of Crohn's and ulcerative colitis that involve the combination of environmental, immune system and bacterial factors effect the person/people that have genetic susceptibility.  We are in desperate need to determine the cause of IBD.  At least if the main cause is identified, scientific studies can be lead in the appropriate direction, with hopes that an effective cure would soon be developed.  
It's frustrating to read all this literature on the studies being done (I'm sort of obsessed with researching this disease). I believe that scientists all over the world are not just twiddling their thumbs in the lab.  I think there are some hard working, determined scientists all over the world, especially in countries that are seeing a growing population of people with this life changing disease, that are committed to finding the true & actual cause.  The frustration, that I'm sure a lot of  these people experience when they think they are on to something and feel confident in the results that were found, to just have those findings tossed in the trash because followup studies confirm something different.  Oh, and not to mention the millions of dollars in research costs that is spent to conduct these studies. 
I'd imagine this has happened thousands of times.  It wasn't just yesterday that they started researching IBD. 
I have hope though..Even although the cause has not been determined as of yet.  I know that someone, sometime soon, will find those golden results that everyone has been anxiously waiting for.  I pray that  God would take any discouragement that may fester in the minds of these people, who have dedicated their lives to helping people get well.  Let that passion to help people only increase and drive these brilliant people to find the answer.  I pray that God would lead these researchers to that answer that will result in millions and millions of people getting better and having the life that was intended for them =  HEALTH & COMPLETE WHOLENESS OF THE BODY!


Article Highlights
  • "(IBD) – are common causes of chronic ill-health, especially in Scottish children, where the incidence of Crohn’s has increased by 500 per cent in the past 50 years."
  • ".... Edin­burgh University will work with two international teams of clinicians and scientists in the £15 million programme, to help identify tell-tale signs in the blood or bowels of patients that point towards the two diseases and could help early diagnosis."
  • "...... mole­cules or proteins – known as bio­markers – that are specifically associated with the development of bowel diseases, .... to track how the illnesses progress in patients over time. In this way, the team hopes to spot the most markers for predicting progression of the disease."
  • "The scientists will use ­cutting-edge scientific techniques – including DNA, protein and microbiological analysis."
  • ".... biomarkers could also make it easier to predict how serious a patient’s illness could become, .. predict their response to treatment,... clues about the possible causes of IBD, .....  pinpoint new targets for better treatments."
  • "Scotland has among the ­highest rates of IBD in the world"



Scientists develop warning system for bowel disease

Picture: Getty
Picture: Getty
Scottish researchers are ­moving closer to finding new ways of diagnosing and treating patients with debilitating bowel conditions.
Crohn’s disease and ulcerative colitis – together known as inflammatory bowel disease (IBD) – are common causes of chronic ill-health, especially in Scottish children, where the incidence of Crohn’s has increased by 500 per cent in the past 50 years.
Researchers in Edinburgh are now taking part in studies to identify early changes in the bowels and blood of patients which would lead to earlier dia­gnosis, better treatment and more information on the potential causes of the conditions.
Symptoms of IBD include stomach pain, weight loss, ­diarrhoea and extreme ­tiredness. Drugs can be used to treat the symptoms, but often patients require major surgery to relieve their suffering.
Now researchers from Edin­burgh University will work with two international teams of clinicians and scientists in the £15 million programme, to help identify tell-tale signs in the blood or bowels of patients that point towards the two diseases and could help early diagnosis.
They hope to identify mole­cules or proteins – known as bio­markers – that are specifically associated with the development of bowel diseases, and to track how the illnesses progress in patients over time. In this way, the team hopes to spot the most markers for predicting progression of the disease.
The scientists will use ­cutting-edge scientific techniques – including DNA, protein and microbiological analysis.
These biomarkers could also make it easier to predict how serious a patient’s illness could become, and to predict their response to treatment. As well as providing clues about the possible causes of IBD, the researchers hope to pinpoint new targets for better treatments.
Scotland has among the ­highest rates of IBD in the world, though the reasons behind this remain unclear.
It is thought environmental factors, such as diet or levels of vitamin D, may play a part in causing conditions which affect one in every 100 to 200 people.
Professor Jack Satsangi, professor of gastroenterology at Edinburgh University, said: “Crohn’s disease and ulcerative colitis are now common causes of chronic ill-health throughout the world, and in Scotland incidences are increasing rapidly.
“The fact the EC has chosen to support two studies involving Scottish patients highlights the fact that the impact of diseases in this country is recognised to be high, and that current therapies are often not successful.”
Thousands of newly-diagnosed patients across Europe and North America are to be recruited for two research trials, which will be run by scientists and clinicians from the UK, Sweden, Belgium, Spain and Norway.


#GAPS DIET NATASHA CAMPBELL-McBRIDE DISCUSSES GAPS/IMMUNITY - GUT/BRAIN/BODY CONNECTION *EXCELLENT AUDIO*

I'm a HUGE fan of this woman, Natasha Campbell-McBride, the creator of the GAPS Diet - Gut and Psychology Syndrome/ Gut and Physiology Syndrome.  She is so smart and has helped so many people get their health back.  Essentially, Dr. Campbell-McBride and GAPS focuses on the health of our gut/digestive system.  The majority of our immune system is in our gut and is THE MOST important when looking at many diseases. Getting our gut flora balanced is necessary for healing an array of conditions.. Some conditions - Multiple Sclerosis, Rheumatoid Arthritis, Fibromyalgia, Lupus, Crohn's, ADHD, Schizophrenia, Depression  

In this audio, Dr. Mercola interviews Dr. Natasha on immunity and GAPS.  She explains why our digestive system, and the health of it, will have a direct effect on our overall health.  It's very easy to understand and the diet itself is not complicated either.  Listen to how logical her theory behind the connection between our gut and brain/body is.  It's almost common sense!  She also talks about fermentation and why our body needs fermented foods (not commercially fermented foods btw) to stay balanced to achieve healing of the body and to maintain health.  

I love her... Listen to her last words of wisdom!        THERE IS NO SUCH THING AS AN INCURABLE ILLNESS.            THERE IS NO DISEASE THAT THE BODY CANNOT HEAL.  SHE'S RIGHT ON THE MONEY! $$$$$$$MONEY$$$$$$$$





Monday, May 6, 2013

Fecal Transplantation Helps Kids w/ Ulcerative Colitis #UC study shows

Sounds promising from everything i've read and continue to read.  
  • How do they get the fecal microbes into the person? According to the article, this is how it's done.  "To perform the transplant, a stool sample must be provided by a healthy adult, usually a family member or close friend. It is mixed with a saline solution and filtered to remove particles that could block the tube. It is given to the patient as an enema in a process that takes more than an hour." 
"Hey sheester, can you s*** in this cup please?"  How does one go about obtaining someones poop?  Hand them the bag with the sample cup and say "# 2 ..not 1."  If they look at you weird and they will, i'm certain.  Say "just do it, it's for a good cause"  



The ultimate probiotic: Unusual treatment helps kids with ulcerative colitis, study shows | MLive.com:

GRAND RAPIDS, MI – Life can be miserable for a kid who has ulcerative colitis.
Bouts of severe diarrhea, cramping and pain can cause them to miss school or avoid social activities. Medications to treat the condition can cause severe complications. The disease can delay growth. Some kids eventually have to undergo surgery to remove their colon.
That is why an alternative, drug-free treatment is raising hope – even as it raises eyebrows among those unfamiliar with it.
At  Helen DeVos Children’s Hospital, a pediatric gastroenterologist is getting good results for patients using fecal transplants. Stool from a healthy donor – often a parent - is given to the patient through an enema in an attempt to restore healthy bacteria in the child’s intestine.
“It’s the ultimate probiotic,” said Dr. Sachin Kunde.
Kunde conducted the first clinical trial in the country to study the use of fecal microbial transplantation on children with ulcerative colitis. Only 10 patients were involved in the trial, but the results were promising.
The symptoms cleared up in three of the children – and they stayed symptom-free for at least a month. Another six saw improvements, which also lasted at least a month. For example, the number of daily bowel movements may have dropped from 10 to five, Kunde said. One child was unable to retain the enema.
The results of the study were published online by the Journal of Pediatric Gastroenterology and Nutrition and will be featured in the June print edition.
The study has stirred excitement among parents of children and young adults with ulcerative colitis, a form of inflammatory bowel disease that affects the lining of the large intestine or rectum.
“We had at least 50 patients in one year calling to be enrolled in the study,” Kunde said. “They want it because they don’t want medication. They think this is a fix.”
But Kunde balanced hope with caution. A larger study is needed to test the treatment’s effectiveness, he said. He has applied for funding for further research and is looking into whether the experimental treatment can be offered outside of a research setting.
Kunde said he first thought of using fecal transplants to treat ulcerative colitis during his fellowship at Emory University in Atlanta. They have previously been used experimentally to treat C. difficile infections.
Within a month of joining DeVos Children’s Hospital in 2011, he proposed the clinical trial to the Spectrum Health institutional review board. He also had to obtain approval from the Food and Drug Administration, because human stool is considered a drug and a biologic.
To perform the transplant, a stool sample must be provided by a healthy adult, usually a family member or close friend. It is mixed with a saline solution and filtered to remove particles that could block the tube. It is given to the patient as an enema in a process that takes more than an hour.
“We believe that the procedure may restore ‘abnormal’ bacteria to ‘normal’ in patients with ulcerative colitis,” Kunde said.
The pilot study involved 10 children and young adults, ages 7 to 20. They received a treatment a day for five days, and then their symptoms were evaluated.
Hospital staff made sure the patients did not see or smell the fecal transplant, which decreased anxiety and uneasiness about it. Kunde said awareness about the treatment is needed so people will readily see it as an acceptable option.

However, many struggling with severe symptoms of ulcerative colitis – adults and children – don’t need convincing, Kunde said. The disruption of life can be a significant psychological burden on patients and their families.
“People want this to be gone,” he said. “I don’t know if it will be gone or not. But it is a new hope for them.
“If we can help at least 30 percent of the patients, that is important.”
Contact Sue Thoms: Email. Twitter. Facebook.
http://www.mlive.com/news/grand-rapids/index.ssf/2013/04/fecal_transplant_-_the_ultimat.html



Wednesday, May 1, 2013

Researchers Find Genetic Link Specific in Identifying Johne's Disease (Disease caused by MAP) in Cattle

John's the man!!!
Ewwww  think about it for a second.  $220 million each year is spent on sick cows that are affected by MAP bacteria (bacteria that causes Johnes Disease).  How many cows are we talking about here?? A LOT! No wonder the # of people with Crohn's Disease is quickly increasing.  All the freaking cows milk is tainted.  

Will vaccinating cattle protect them from such a nasty tough as steel bacteria like MAP though. Say the vaccinated cows show no signs of illness at all, but they have trace amounts of the MAP bacteria living in them that doesn't bring on Johne's Disease.  Will that small amount of bacteria that is passed to humans through dairy intake be enough to make people sick?  I'm just thinking out loud...  Just wondering how this discovery is going to affect the dairy industry.  Just have to wait and see. 




Posted: Wednesday, April 17, 2013 3:00 am
Detecting the costly, contagious Johne's disease in cattle is now easier, thanks to U.S. Department of Agriculture (USDA) scientists.
Johne's disease, also known as Paratuberculosis, is estimated to cost the U.S. dairy industry more than $220 million each year. It also affects sheep, goats, deer and other animals, causing diarrhea, reduced feed intake, weight loss and sometimes death.
Microbiologist John Bannantine and his colleagues at the Agricultural Research Service (ARS) National Animal Disease Center (NADC) in Ames, Iowa, discovered an antibody that's 100 percent specific in detecting Johne's disease. This is the first time a specific antibody that binds only to Mycobacterium avium subspecies paratuberculosis (MAP), the pathogen that causes the disease, has been discovered. A patent has been awarded to scientists for the antibody, which could greatly benefit the improvement of diagnostic tests that confirm the presence of MAP.
Previous efforts to detect Johne's disease were hindered because all antibodies used to identify MAP strains also reacted to environmental mycobacteria, according to Bannantine, who works in NADC's Infectious Bacterial Diseases Research Unit. Some of those antibodies also reacted to the disease pathogen responsible for bovine tuberculosis (TB) and caused false-positive results.
Other research, conducted by NADC microbiologist Judy Stabel, focused on ensuring that Johne's disease vaccines do not cross-react with tests for bovine TB, a disease problem in states where wild deer infect cattle.
Stabel and her team vaccinated calves with an effective commercial Johne's vaccine to test cross reactivity with TB tests. They took blood samples for a year and then measured immune and serological responses of calves using novel TB tests.
Scientists found no cross reactivity with the TB serology tests, demonstrating that animals could be vaccinated against Johne's disease without interfering with bovine TB testing. Similar results were found with the skin test used to detect TB in cattle.
Read more about this research in the April 2013 issue of Agricultural Research magazine.

Saturday, April 20, 2013

Food Additive, Carrageenan, May Be Linked To Gastrointestinal Problems - RT Please


Carrageenan?  I've never heard of it.  Just something else to look out for in the ingredients.  
Doubts surface about common food additive's safety

CHICAGO — Sara Baker says the light went on in her head after a cup of hot cocoa set off a storm in her stomach.
"I went back and looked at the package and there it was: carrageenan," said Baker, a career services coordinator from Bloomington in central Illinois.
Baker been taking medication for ulcerative colitis for years but still suffered debilitating digestive flare-ups without warning. She had read warnings about carrageenan in a natural health newsletter but didn't take them seriously.
This time, though, "it really clicked," she said of the ingredient, which researchers say has not been conclusively linked to gastrointestinal problems in humans. "It took awhile to learn just how many things it's in, but now that know, I can avoid it and I no longer have the problems."
Experiences like Baker's have led some people with gastrointestinal problems to sidestep mainstream medical advice and avoid carrageenan, a seaweed-derived texturizer found in meat, dairy and other processed foods — including some organic products.
For scientists, however, these are just anecdotes. Though studies on lab animals and human cells have suggested that carrageenan can cause gastrointestinal inflammation, many researchers and physicians say it's unclear whether it has the same impact on people who consume it.
Scientists at the University of Illinois at Chicago and University of Chicago are seeking to address that question with a controlled clinical trial that Baker is participating in.
"I believe it's worth investigating and doing the science to find out," said Dr. Stephen Hanauer, a medical professor and chief of gastroenterology and nutrition at University of Chicago Medicine.
His co-researcher, UIC physician and professor Joanne Tobacman, has been looking at the health effects of carrageenan for more than a decade and is concerned enough to have petitioned the U.S. Food and Drug Administration in 2008 to prohibit the use of carrageenan in food.
Her petition cited decades of science, including her own, on carrageenan-induced inflammation in animals and cells. In June, the FDA responded with a letter of denial.
"It was disappointing that with such clear evidence about the effects of carrageenan on inflammation, the FDA did not restrict the use of carrageenan, particularly in infant formula," Tobacman said.
The additive, which lends a uniform, creamy texture to food, can be found in soy milk, yogurt, ice cream, cheeses, some meats, diet soft drinks and even toothpaste.
Michael Adams, deputy director of the FDA's Office of Food Additive Safety, said the petition did not make a compelling case to re-examine the safety of carrageenan. "It has been reviewed repeatedly by FDA scientists and other international organizations, and in the judgment of those experts there hasn't been a problem," he said.
Adams called a rat study from 2006 "the gold standard for us because it exactly mimics the exposure consumers are going to get when they eat these carrageenan-containing foods."
That study was funded and performed by a manufacturer of carrageenan.
Adams said he didn't know that but added: "If you look at the science and you believe it's well done it doesn't matter where the money comes from."
The Cornucopia Institute, a Wisconsin-based organic industry watchdog group, on released a report on carrageenan called "How a Natural Food Additive Is Making Us Sick."
Charlotte Vallaeys, Cornucopia's director of food policy, said the group felt "an ethical obligation" to raise awareness. "If government agencies weren't going to protect consumers, then it seemed we needed to let consumers know about this so they could protect themselves."
The institute also is challenging the FDA's denial of Tobacman's petition. Among other objections, Cornucopia's letter to the agency asks why officials did not consider any studies on carrageenan published in the last four years.
Adams said the FDA's scientific evaluation in response to the petition was finished in May 2009, after which it spent more than three years in what he calls the "administrative chain."
Regarding infant formula, Adams said Europe takes a different approach to food additives than the U.S., sometimes banning a substance when toxicity studies raise concerns but are not conclusive.
"The Europeans do their business that way but we don't," he said. "We would base it more on the science we have rather than waiting for science to be developed."
While the Chicago researchers proceed with their work and advocates seek federal action, some consumers and activists have made an impact on their own by lobbying manufacturers directly to phase out the ingredient.
Last month Stonyfield joined a number of manufacturers who have removed or have pledged to remove carrageenan from their organic products. Organic Valley says it has removed the ingredient from most food items but is still working on reformulations for soy milk, chocolate milk and one version of its whipping cream.
A representative of the organic dairy company Horizon Organic and soy milk maker Silk (each majority owned by Dean Foods) said both view carrageenan as safe and would not comment on any plans to remove it.
The U.S. National Organic Standards Board reapproved the use of carrageenan in most organic foods last year but decided to prohibit its use in organic infant formula. (WHAT????
Carrageenan manufacturers, the FDA, the United Nations food additives committee and some scientists say it is safe, as evidenced by centuries of use.
Still, many gastroenterologists are not convinced carrageenan is dangerous.
"There are some studies in rats and mice showing that carrageenan exposure can lead to GI inflammation that mimics things like Crohn's" disease, said Dr. Sunanda Kane, a Mayo Clinic physician and medical adviser to the Crohn's and Colitis Foundation of America. "But it's never been shown on human tissue in humans walking around."
Over the last 50 years, incidence of inflammatory bowel disease has risen as people eat more processed food, Kane said. "But is it carrageenan or that we don't exercise or have lots of other additives and preservatives or fructose in our food supply?"
In Hanauer and Tobacman's study, people whose ulcerative colitis is in remission are being put on a carrageenan-free diet, then given either a controlled dose of carrageenan or a placebo.
So far, the research has been hampered by low volunteer rates — currently, fewer than 20 subjects. Hanauer notes that the prospect of re-inflaming one's inactive ulcerative colitis is not particularly attractive.
But Baker, who was one of more than 120 people who responded when Cornucopia asked to hear from those with carrageenan-related digestive problems, said she was willing to go through it to help establish human science on the topic.
"I believe there are people who are as sick as I was, or even worse, who need this information," she said.

Doubts surface about common food additive's safety | SouthCoastToday.com:

'via Blog this'

Friday, April 19, 2013

Patient Taking Adalimumab (Humira) - Questioning Why Makers of The Drug Are Preventing Disclosure of Trial Data.

......He isn't the only one wondering what in the hell is up AbbVie's sleeve.  

I don't even take the drug, I never will, but what's the deal with withholding data like this.  Let's see it, AbbVie!  Shouldn't trial information be available to the general public in order for people to make informed decisions regarding the best treatment choice? How can people do that, when the information isn't there!?  
I visualize a bunch of robots.. The robots are the patients, they take what they are given and do as they are told.  God forbid people ask questions and want the answers and demand them.  People have the right to know this information... right?  For the people that take this stuff, they put the chemical into their body everyday and they aren't allowed to know everything there is to know about the stuff?  That just doesn't sit well with me and it shouldn't sit well with you either.  
It's sketchy.. The whole drug/medicine/medical industry can't be trusted.  They really are starting to show their faces by trying to put a curtain in front of them.  When people are told "No" to something that is usually otherwise available, it just holds a red flag to it and makes people wonder things, speculate what the reasons may be for withholding.  AbbVie is making it quite clear that they have something to hide.  Logically, what reason would they have for wanting to hold back trial data... unless the data shows something that could result in an unfavorable response.  It might make people requestion if Humira is for them or not.  Now if the data were positive, wouldn't the company want to display it for the world to see?  It would lead to more sales and continued use of the treatment.
Let's face it, your doctor isn't running down the whole list of possibly negative consequences of taking the drug before you start it.  He/she just isn't and that's that. They shine a positive outlook on the drug because they want you to take it.  In addition, THEY don't even know the ins and outs of the drug.  That's really our job and our responsibility as patients to do our homework.  Some people do their research and some  people don't, but for the ones who do, not having this information easily available or just not showing "all" of the information is just giving people a false/skewed view of what the drug really is.  
Not cool!


A patient with Crohn's disease is concerned about the attempt by the makers of adalimumab to prevent disclosure of trial data submitted during the drug's approval process, according to a personal view piece published online April 16 in BMJ.
THURSDAY, April 18 (HealthDay News) -- A patient with Crohn's disease is concerned about the attempt by the makers of adalimumab to prevent disclosure of trial data submitted during the drug's approval process, according to a personal view piece published online April 16 in BMJ.
Alex Lomas, a patient with Crohn's disease from London who has been taking adalimumab for three years with beneficial results discusses the lack of trial data available on biologicals.
Noting that part of the National Institute for Health and Care Excellence's approval for use of adalimumab for Crohn's disease was the recommendation to set up a registry to track long-term outcomes and relapse rates after treatment withdrawal, Lomas reports that registries are fragmented or are still at pilot stage. He adds that the attempt by AbbVie, the maker of adalimumab, to prevent the European Medicines Agency from disclosing recent trial data submitted during the drug's approval process is cause for concern and is preventing patients and health care providers from making informed decisions about the use of this treatment.
"As the drug industry and medical profession as a whole move towards the registration of all trials, and the publication of all trial data -- in no small way thanks to the All Trials initiative (www.alltrials.net) -- this decision by AbbVie is a backwards step and is offensive to trial participants, patients, and the wider public who ultimately pick up the tab," Lomas writes.

Health News Copyright © 2013 HealthDay. All rights reserved.

The patient Alex Lomas is taking a biological drug for Crohn’s disease, and he wants to know why the maker is trying to prevent disclosure of trial data that may well affect him
I have an obsession with data. I have instruments in my house so I know how hot each room is and to warn me if the fridge door has been open for too long. I record my weight and blood pressure using devices connected to the internet so that I can monitor long term trends. I use my smartphone to track how much walking and exercise I do.
I was diagnosed with Crohn’s disease about 20 years ago, when awareness of inflammatory bowel diseases was not as high as it is today.1 The treatment decisions made at the time of my diagnosis had unfortunate side effects for me as a teenager. High doses of prednisolone led to Cushing’s syndrome, and I was mercilessly teased about my appearance at school. With time came a reduction in the dose of steroids required, but I had to take them throughout my 20s, and control of my symptoms was still inadequate.
As a patient with Crohn’s disease, I take an active interest in my day-to-day health, but I also routinely scan news media and journal sites for new treatments and for changes to current best practice in the management of my condition. I often arrive at appointments with my consultant armed with PDFs printed from the BMJ, the Cochrane Collaboration, and the National Institute for Health and Care Excellence (NICE) to discuss the latest trials and treatment options. Yes, I’m afraid I’m one of those patients.
Three years ago my consultant suggested a new course of treatment with adalimumab (Humira), an anti-TNFα monoclonal antibody. My local primary care trust approved this new drug, which costs £352 per injection, and which I administer myself by injection each fortnight.2 Since I started taking adalimumab I have the least symptoms since diagnosis. I am no longer taking steroids; I have started to recover from 15 years of side effects; and I spend less time in clinical care and off work on sick leave.
However, anecdotes are not the foundation of evidence based medicine, and nor are they a rational basis for evaluating the cost of a treatment. On 1 April 2013 responsibility for commissioning transferred from my primary care trust to the local clinical commissioning group, bringing into sharp focus the question of whether the NHS is getting value for money in continuing my treatment.
Equally importantly, I want to be able to evaluate the benefits and risks of these costly pharmaceuticals with which I inject myself regularly. Biologicals are relatively new, and have failed spectacularly in clinical trials.3 Who knows what 20 or 30 years of data from clinical use might bring? The most recent Cochrane review of biologicals looked at nine studies, and, although it found that they were effective, it noted that none of the trials allowed for an assessment of long term adverse events nor had any trials been undertaken that compared efficacy among the available biologicals.4 My consultant recently told me that no trials had been done to determine what the minimum effective dose of adalimumab was, nor would there likely ever be; a drug company has no interest in showing you can take less of something.
Part of NICE’s approval for the use of adalimumab in treating Crohn’s disease was the recommendation that a register of patients being treated with biologicals be set up to track long term outcomes and relapse rates after withdrawal of treatment, something patient groups welcomed.5 Unfortunately it seems that such registers are fragmented, with registers of patients with rheumatoid arthritis held independently from registers of patients with inflammatory bowel disease, or are still at pilot stage.6
As a patient, I need clinicians to interpret trial data and systematic reviews of new and existing treatments so we can come to appropriate decisions about my treatment, but what if even experts don’t get to see the whole picture? How can we even know what trials are being run?
I was therefore dismayed to learn that Abbvie, the maker of adalimumab, are seeking a legal injunction to prevent the European Medicines Agency from disclosing trial data submitted during the drug’s approval process.7 With such a new drug, it is vital that all data, whether it’s good news or bad, are made available so that I, my consultant, and the care commissioning group can make informed decisions about the efficacy and cost effectiveness of treatments.
As the drug industry and medical profession as a whole move towards the registration of all trials, and the publication of all trial data—in no small way thanks to the All Trials initiative (www.alltrials.net)—this decision by Abbvie is a backwards step and is offensive to trial participants, patients, and the wider public who ultimately pick up the tab.

Notes

Cite this as: BMJ 2013;346:f2336

Footnotes

  • Competing interests: I have read and understood the BMJ Group policy on declaration of interests and have no relevant interests to declare.
  • Provenance and peer review: Not commissioned; not externally peer reviewed.

References



I’m a patient: show me the trial data | BMJ:

'via Blog this'